Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026
Deferred tax liabilities remains negative
Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.
Context
- Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred tax liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Tax Liabilities vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's Mar 2026 deferred tax liabilities of $0 is the highest of the 2 companies compared; the peer median is $0.
- Deferred tax liabilities amounts to 0.0% of total assets for INDP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INDP) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 39.13M | 9.63M | 13.36M | 5.79M | 8.51M |
| Short-term Investments | 0 | 16.81M | 0 | 0 | 0 |
| Net Receivables | 21.06K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 148.4K | 0 | 0 | 0 | 0 |
| Total Current Assets | 40.39M | 27.24M | 14M | 6.62M | 9.31M |
| Property, Plant & Equipment (Net) | 172.89K | 81.31K | 173.94K | 82.18K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 16.48K | 738.25K | 754.73K | 638.25K | 0 |
| Total Non-current Assets | 189.37K | 819.56K | 928.67K | 720.43K | 0 |
| Total Assets | 40.58M | 28.06M | 14.92M | 7.34M | 9.31M |
| Account Payables | 2.64M | 1.38M | 806K | 870.23K | 544.06K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 128.93K | 40K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 498.73K | 1.22M | 1.21M | 1.37M | 4.03M |
| Total Current Liabilities | 4.6M | 3.43M | 2.77M | 3.39M | 6.16M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 72.86K | 0 | 73.35K | 0 | 0 |
| Total Liabilities | 4.68M | 3.43M | 2.85M | 3.39M | 6.16M |
| Common Stock | 82.59K | 84.01K | 84.01K | 120.14K | 21.67K |
| Retained Earnings | (15.67M) | (29.99M) | (45.42M) | (60.44M) | (81.29M) |
| Accumulated OCI | 0 | 96.43K | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 35.9M | 24.63M | 12.08M | 3.94M | 3.15M |
| Total Debt | 169.33K | 80.49K | 175.05K | 84.16K | 0 |
| Net Debt | (38.96M) | (9.55M) | (13.19M) | (5.7M) | (8.51M) |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.